Pharsight

Ravicti patents expiration

RAVICTI Litigations

Can you believe RAVICTI received compensation for the extended wait time during the regulatory approval process?

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5968979 HORIZON THERAP US Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
Feb, 2015

(9 years ago)

US10183006 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US10045958 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US9561197 HORIZON THERAP US Methods of therapeutic monitoring of phenylacetic acid prodrugs
Sep, 2030

(6 years from now)

US10183003 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US10183002 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US10183004 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US8642012 HORIZON THERAP US Methods of treatment using ammonia-scavenging drugs
Sep, 2030

(6 years from now)

US10045959 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US9999608 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US9962359 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US10183005 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Sep, 2030

(6 years from now)

US10668040 HORIZON THERAP US Treatment of urea cycle disorders in neonates and infants
Sep, 2030

(6 years from now)

US9254278 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Mar, 2032

(7 years from now)

US8404215 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging
Mar, 2032

(7 years from now)

US9326966 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Mar, 2032

(7 years from now)

US9095559 HORIZON THERAP US Methods of therapeutic monitoring of nitrogen scavenging drugs
Mar, 2032

(7 years from now)

Ravicti is owned by Horizon Therap Us.

Ravicti contains Glycerol Phenylbutyrate.

Ravicti has a total of 17 drug patents out of which 1 drug patent has expired.

Expired drug patents of Ravicti are:

  • US5968979

Ravicti was authorised for market use on 01 February, 2013.

Ravicti is available in liquid;oral dosage forms.

Ravicti can be used as dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder, treatment of a nitrogen metabolism disorder, treatment of a urea cycle disorder.

The generics of Ravicti are possible to be released after 09 March, 2032.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-157) Apr 28, 2024
New Patient Population(NPP) Dec 21, 2021
Orphan Drug Exclusivity(ODE-42) Feb 01, 2020
NE(NE) Feb 01, 2016
Orphan Drug Exclusivity(ODE) Feb 01, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Market Authorisation Date:

01 February, 2013

Treatment:

Treatment of a nitrogen metabolism disorder; Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage:

LIQUID;ORAL

How can I launch a generic of RAVICTI before its drug patent expiration?

More Information on Dosage

RAVICTI family patents

Family Patents